GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects
Background
Major depression affects about 10 percent of the adult population and is the second leading cause of disability in U.S. adults, according to the World Health Organization. Despite the availability of several different classes of antidepressant drugs such as selective serotonin reuptake inhibitors (SSRIs), 30 to 40 percent of adults are unresponsive to these medications. Moreover, SSRIs typically take weeks to work, which increases the risk for suicide.
Enter NMDA (N-methyl-D-aspartate) receptor modulators. In the 1970s, researchers linked the receptors to learning and memory. Biotech and pharmaceutical companies in the 1980s attempted to apply chemical blockers to these receptors as a means to prevent stroke. But blocking these receptors led to the opposite effect—–the rise of cardiovascular disease. Research in the field dampened until a glutamate receptor antagonist already approved for anesthesia, and known on the streets as “Special K”, ketamine, made headlines in the early 2000s. Human clinical studies demonstrated that ketamine can ward off major and bipolar depressive symptoms within 2 hours of administration and last for several days. Ketamine is fraught with serious side effects including excessive sleepiness, hallucinations, and substance abuse behavior.
“Ketamine lit the field back up,“ said Joseph Moskal, Ph.D., a molecular neurobiologist at Northwestern University and senior study author. “Our drug, GLYX-13, is very different. It does not block the receptor ion channel, which may account for why it doesn’t have the same side effects.”
Moskal’s journey with GLYX-13 came about from his earlier days as a Senior Staff Fellow in NIMH’s Intramural Research Program. While at NIMH, he created specific molecules, monoclonal antibodies, to use as new probes to understand pathways of learning and memory. Some of the antibodies he created were for NMDA receptors. When he moved to Northwestern University, Moskal converted the antibodies to small protein molecules. Comprised of only four amino acids, GLYX-13 is one of these molecules.
Previous electrophysiological and conditioning studies had suggested that GLYX-13, unlike ketamine, enhanced memory and learning in rats, particularly in the brain’s memory hub or hippocampus. GLYX-13 also produced analgesic effects. Using several rat behavioral and molecular experiments, Moskal’s research team tested four compounds: GLYX-13, an inactive, “scrambled” version of GLYX-13 that had its amino acids rearranged, ketamine, and the SSRI fluoxetine.
Results of the Study
GLYX-13 and ketamine produced rapid acting (1 hour) and long-lasting (24 hour) antidepressant-like effects in the rats. Fluoxetine, an SSRI that typically takes from 2–4 weeks to show efficacy in humans, did not produce a rapid antidepressant effect in this study. As expected, the scrambled GLYX-13 showed no antidepressant-like effects at all. The researchers observed none of the aforementioned side effects of ketamine in the GLYX-13–treated rats.
Protein studies indicated an increase in the hippocampus of the NMDA receptor NR2B and a receptor for the chemical messenger glutamate called AMPA. Electrophysiology studies in this brain region showed that GLYX-13 and ketamine promoted long-lasting signal transmission in neurons, known as long-term potentiation/synaptic plasticity. This phenomenon is essential in learning and memory. The researchers propose how GLYX-13 works: GLYX-13 triggers NR2B receptor activation that leads to intracellular calcium influx and the expression of AMPA, which then is responsible for increased communication between neurons.
These results are consistent with data from a recent Phase 2 clinical trial, in which a single administration of GLYX-13 produced statistically significant reductions in depression scores in patients who had failed treatment with current antidepressants. The reductions were evident within 24 hours and persisted for an average of 7 days. After a single dose of GLYX-13, the drug’s antidepressant efficacy nearly doubled that seen with most conventional antidepressants after 4–6 weeks of dosing. GLYX-13 was well tolerated and it did not produce any of the schizophrenia-like effects associated with other NMDA receptor modulating agents.
The Latest Bing News on:
Major depression
- Summertime sadness: The less talked about side of seasonal depressionon April 19, 2024 at 1:14 pm
For many, spring is a time of year many look forward to. For a rare group of individuals, however, the blooming trees, warmer tempeatures and later sunsets can ...
- Is Europe Taking Too Long to Adopt TMS for Major Depression?on April 19, 2024 at 9:07 am
Repetitive transcranial magnetic stimulation has been approved for more than a decade in the US, but Europe still needs clear guidelines.
- Inner Cosmos shows its mildly invasive skull implants can treat depressionon April 18, 2024 at 12:30 pm
Inner Cosmos implants treatment devices in human brains, and its neurostimulation tech can be used to treat depression.
- 'Satanic Panic' Psychiatrist Dies; Caplyta Depression Win; Esketamine After Birthon April 17, 2024 at 11:39 am
Bennett Braun, MD, the psychiatrist who promoted "Satanic Panic" when he claimed that dozens of his patients had discovered repressed memories of being tortured by satanic cults, and subsequently lost ...
- Ketamine injection after childbirth can reduce postpartum depression in new mothers by 75%on April 17, 2024 at 8:04 am
One low-dose injection of esketamine administered right after childbirth reduces major depressive episodes, according to a new study. View on euronews ...
- Arrivo Bio doses first subject in Phase IIb major depressive disorder trialon April 17, 2024 at 7:09 am
The trial’s primary endpoint is to analyse the change from baseline on the Montgomery-Åsberg Depression Rating Scale.
- Another Caplyta trial win moves Intra-Cellular closer to FDA filing in major depressive disorderon April 16, 2024 at 11:27 am
Intra-Cellular Therapies has unveiled another positive late-stage trial readout for Caplyta, taking another step toward a potential blockbuster label expansion for the depression drug. | ...
- Ketamine's rapid impact on depression linked to immune system pathwayson April 15, 2024 at 6:18 pm
Study reveals ketamine's potent anti-inflammatory effects on neurological disorders, showing promise for treating major depressive disorder through modulation of neuroimmune pathways.
- Depression Trial Win Moves Intra-Cellular Drug Closer to Label Expansion & Blockbuster Statuson April 15, 2024 at 5:00 pm
High placebo responses common in tests of neuropsychiatric drugs makes any clinical trial in major depressive disorder risky. Intra-Cellular Therapies now has data showing its drug met key goals ...
- First-degree relatives are 9 times more likely to develop a serious form of depression, study sayson April 14, 2024 at 1:54 am
The study is the first and largest to use an entire country's data to confirm genetic transmission of treatment-resistant depression across families and an association with other major psychiatric ...
The Latest Google Headlines on:
Major depression
[google_news title=”” keyword=”Major depression” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Fix the internet
- How to fix error code Mike-01 in xDefianton April 19, 2024 at 12:35 pm
xDefiant Discord have conversed about the Mike-01 error take it up with Ubisoft’s support. not all Ubisoft games are available in the same region as others go to the game’s X account to see if there ...
- Larry Magid: Fixing a slow internet connectionon April 18, 2024 at 10:42 pm
Larry Magid is a tech journalist and internet safety activist. Contact him at [email protected].
- Supply Siders Close To Trump Need To Fix His Dollar Confusionon April 18, 2024 at 10:00 pm
Former Donald Trump NEC head Larry Kudlow wrote the above in 1996, and in the midst of Bill Clinton’s successful economic presidency. To Kudlow’s everlasting credit he didn’t waste time on Clinton’s ...
- AT&T internet lines to Sacramento airport found to be ‘deliberately cut’on April 18, 2024 at 6:47 am
An internet outage at the Sacramento International Airport on Thursday morning is now being investigated by the Sacramento County Sheriff’s. AT&T internet lines servicing SMF were found to be ...
- Dating culture has become selfish. How do we fix it?on April 18, 2024 at 5:09 am
Social media is packed with stories of unbelievably selfish dating behaviour. Here’s what’s going on and how to undo it.
- Terry Savage: Warning on credit repair and chasing rewardson April 17, 2024 at 3:39 pm
Even the zero-interest period on balance transfer cards can get you deeper into trouble. If you don’t pay off the balances within the zero-rate period, you can expect your finance charge to soar ...
- Still facing call and text issues on your Pixel phone? Try this temporary fixon April 17, 2024 at 7:52 am
In the absence of any solution from Google, users have found out that disabling 5G and certain other settings helps fix Pixel network issues.
- $90 Billion vs. the Digital Divide: Is It Enough to Fix Internet Access in the US?on April 13, 2024 at 5:00 am
Congress approved a colossal sum of money that they believe will be enough to connect Americans left out of the modern digital world.
- Your LG TV could be vulnerable to a cyber attack – here's how to fix iton April 12, 2024 at 5:04 am
A software vulnerability that puts personal data at risk has been identified on LG TVs, so update your TV today.
- “Fix It”: 40 Times People Had No Clue How To “Fix It,” But The Internet Had Their Backon April 10, 2024 at 3:50 am
People post pictures of the things that they need help with and the members of this online community provide them with clear instructions on how to take care of the issue. The post “Fix It”: 40 Times ...
The Latest Google Headlines on:
Fix the internet
[google_news title=”” keyword=”fix the internet” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]